Impax Laboratories Inc. has begun shipping authorized generic Renvela (sevelamer carbonate 800 mg tablets), the company announced April 16. Renvela is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
After a patent fight with Genzyme, Impax was granted a license to sell an allotment of a specified number of bottles of an authorized generic version of Renvela tablets.
"We are excited to market this product and provide patients with a more affordable treatment option," said Carole S. Ben-Maimon, M.D., President of Global Pharmaceuticals at Impax. "This product will be an important contributor to our 2014 financial results."
According to IMS Health, U.S. sales of Renvela Tablets, 800 mg, between February 2014 and February 2014 were approximately $907 million.
More articles about phosphate control in dialysis patients
FDA approves new phosphate binder Velphoro for dialysis patients
New chewing gum designed to reduce phosphate levels in chronic kidney disease patients
CEs available Using concordance with dosing techniques to achieve phosphate control